Tonix Pharmaceuticals publishes presentation on TNX-4800 for Lyme disease prevention
TNXP•Tonix Pharmaceuticals published a presentation outlining development plans for its investigational monoclonal antibody TNX-4800. An adaptive Phase 2 field trial is planned pending FDA protocol agreement, and manufacturing targets the first quarter of 2027; human preventive efficacy has not been established.
1. Development plans
Tonix Pharmaceuticals published a presentation on TNX-4800 for Lyme disease prevention. The company plans an adaptive Phase 2 field trial, pending FDA protocol agreement, and targets first-quarter 2027 for investigational product manufacturing.
2. Phase 1 findings
A completed Phase 1 study found no significant clinical or laboratory safety signals in healthy adults. Two seasonal doses are intended to provide protection within two days for at least six months, but human preventive efficacy has not been established.




